Sequence Information

    • DRAMP ID

    • DRAMP18160

    • Name

    • Omiganan (MBI-226/MX-226/CLS001)

    • Sequence

    • ILRWPWWPWRRK

    • Description

    • Omiganan (MBI-226), an analogue of indolicidin, has been proven to be capable of significantly reducing catheter colonization and microbiologically confirmed tunnel infections during catheterization

    • Activity

    • Antibacterial

    • Target Organism

      • [Ref.19524411]Omiganan was most active against staphylococci, with MICs of 2–4, 2–8, 4 and 4 μg/mL against MSSA, MRSA, MSSE and MRSE strains, respectively. The peptide was also inhibitory against other organisms, with MICs of 8–16 μg/mL against E. coli, E. faecalis and E. faecium (including VSE and VRE strains), 128 μg/mL against E. cloacae and S. marcescens and 64 μg/mL against C. albicans.

    • Reference

      • Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models.(PMID: 19524411)
      • New therapies for atopic dermatitis: Additional treatment classes.(PMID: 29248520)
      • Designing antimicrobial peptides: form follows function.(PMID: 22173434)
      • Cationic antimicrobial peptides in clinical development, with special focus on thanatin and heliomicin.(PMID: 21964560)

Clinical Information

    • Medical use

    • Rosacea, Acne vulgaris (II), Genital warts (II)

    • Company

    • Maruho Co., Ltd(developing), Cutanea Life Sciences, Inc.(developing), Mallinckrodt, Micrologix Biotech(Vancouver, BC, Canada)

    • Stage of Development

    • Phase III(catheter-related infections,Failure), Phase III(rosacea, completed), Phase II(atopic dermatitis (AD), usual type vulval intraepithelial neoplasia (uVIN), external genital warts, and acne vulgaris, completed), Phase III(facial seborrheic dermatitis, recruiting)

    • Comments

    • MX-594AN significantly reduced acne lesions compared with vehicle controls in a phase IIb trial in 2003 and was licensed to Cutanea Life Sciences in late 2005.

    • Clinical Trials

    • NCT02576847
    • NCT03091426
    • NCT01784133
    • NCT00608959
    • NCT00231153